Growth of almost a fifth in international markets helped Alembic Pharmaceuticals Limited increase revenues by 17% to INR53.9bn ($740m) in the Indian company’s financial year ended 31 March 2021, as an uptick in partnership-driven non-US geographies more than compensated for pricing pressures experienced in Alembic’s US generics business.
US generics sales, by far Alembic’s largest business by revenues, increased by 9% to INR21.6bn, despite those challenges for the...




